We retrospectively reviewed the patient with breast cancer, who was receiving adjuvant RT and CDK4/6i at Far Eastern Memorial Hospital (FEMH) in 2024 and reported the associated cancer treatment-related toxicity. Here, CDK4 is linked to breast carcinoma.